Cardiovascular Research

Lack of significant effects of superoxide dismutase and catalase on development of reperfusion arrhythmias.

Authors: J M Hagar|||S L Hale|||J P Ilvento|||R A Kloner

Affiliations: + Expand

Abstract

It has been reported that agents having the ability to scavenge oxygen-derived free radicals reduce the severity of ventricular arrhythmias that occur after brief coronary occlusion and reperfusion. Superoxide dismutase plus catalase (SOD + CAT) or placebo was administered in a blinded randomized fashion prior to coronary occlusion in rats (n = 25 each group) undergoing a 5-min left coronary occlusion followed by 15 min of reperfusion. During reperfusion, ventricular tachycardia (VT) developed in 96% of animals in both groups. Reperfusion ventricular fibrillation (VF) developed in 60% of the placebo group vs 56% in the SOD + CAT group (p = 1.0). Irreversible VF occurred in 40% of the placebo group vs 20% in the SOD + CAT group (p = 0.22). Atrioventricular block occurred in 12% of placebo and 4% of SOD + CAT animals (p = 0.61). There were no significant difference between groups in duration of VT (85 +/- 15 s (mean +/- SEM) placebo vs 81 +/- 14 s SOD + CAT, p = 0.81), total duration of VT plus VF (391 +/- 76 s placebo vs 256 +/- 64 SOD + CAT, p = 0.45) or numbers of single ventricular ectopic beats (65 +/- 15 placebo vs 97 +/- 18 SOD + CAT, p = 0.18). Heart rate at reperfusion was slightly higher in control than SOD + CAT animals (340 +/- 33 vs 319 +/- 32, p = 0.02). Risk zone size, determined by Monastral blue injection, was equal in both groups (34 +/- 2% of ventricular mass). The occurrence of reperfusion VF in this model could not be predicted by heart rate at reperfusion (331 +/- 33 VF animlas vs 328 +/- 36 no VF, p = 0.77), or by risk zone size (34 +/- 2%, VF and no VF groups).(ABSTRACT TRUNCATED AT 250 WORDS)

---

Chemical List

Anti-Arrhythmia Agents|||Catalase|||Superoxide Dismutase

---

Reference List

Circ Res. 1987 Mar;60(3):375-83|||Circ Res. 1984 Mar;54(3):277-85|||Circ Res. 1989 Jul;65(1):146-53|||Circ Res. 1985 Feb;56(2):184-94|||Am J Physiol. 1986 Oct;251(4 Pt 2):H863-8|||Br J Pharmacol. 1987 May;91(1):49-59|||J Mol Cell Cardiol. 1988 Jan;20(1):35-45|||Angiology. 1988 Jul;39(7 Pt 2):684-99|||J Mol Cell Cardiol. 1988 Dec;20(12):1163-78|||Circ Res. 1989 Jan;64(1):86-96|||J Mol Cell Cardiol. 1987 Jun;19(6):615-25|||Am J Physiol. 1989 May;256(5 Pt 2):H1344-52|||Cardiovasc Res. 1990 Feb;24(2):156-64|||J Mol Cell Cardiol. 1984 Jun;16(6):497-518|||Proc Natl Acad Sci U S A. 1987 Mar;84(5):1404-7|||J Mol Cell Cardiol. 1985 May;17(5):485-93|||Angiology. 1988 Dec;39(12):1005-13|||Am Heart J. 1988 Jan;115(1 Pt 1):20-9|||Free Radic Biol Med. 1987;3(2):153-9|||Cardiovasc Drugs Ther. 1987 Aug;1(2):133-9|||Cardiovasc Res. 1988 Jul;22(7):447-55|||Circ Res. 1987 Jul;61(1):50-4|||Basic Res Cardiol. 1988 Mar-Apr;83(2):149-57|||Circulation. 1984 Sep;70(3 Pt 2):I91-5|||Cardiovasc Drugs Ther. 1988 Dec;2(5):615-21|||Circ Res. 1986 Mar;58(3):331-40|||Circulation. 1981 Feb;63(2):333-40|||Basic Res Cardiol. 1988 Mar-Apr;83(2):141-8|||J Mol Cell Cardiol. 1988 Nov;20(11):1053-67|||Am J Physiol. 1989 Jan;256(1 Pt 2):H21-31|||Circ Res. 1986 Jan;58(1):148-56